Q4 2025 Nanoform Finland Oyj Earnings Call Transcript
Key Points
- Nanoform Finland PLC (FRA:4YL) has launched a 'breakthrough strategy' focusing on small and large molecules, aiming to make nano farming technology globally dominant.
- The company achieved a record level of revenue and other operating income in 2025, indicating strong financial performance.
- Nanoform has expanded its commercial reach by securing deals with five countries, including a new distributor in South Korea, enhancing its presence in Asia.
- The company received a EUR5 million loan from Business Finland to strengthen its kernel IP, supporting future growth and innovation.
- Nanoform's biologics technology has shown promising pre-clinical data, positioning the company well in the subcutaneous delivery market for monoclonal antibodies.
- The company is targeting a cash burn below EUR10 million in 2026, indicating ongoing financial challenges.
- Nanoform's income growth target of more than 50% CAGR until 2030 may be challenging to achieve, especially in the early years.
- The company has not yet secured GMP stamps for its Bioline platform, delaying its readiness for human trials.
- Milestone achievements are uncertain, as they depend on both existing and new projects, which may impact financial projections.
- The transition from building to cashing in on investments may take time, as the company needs to strategically plan and secure marketing authorizations for its products.
Your line is muted. Welcome to the conference call. (Operator Instructions) Now I will hand the conference over to the speakers. Please go ahead.
Good morning all and a warm welcome to Nanoform's fourth quarter and full year 2025 report.
Presentation. My name is Henry von Hartmann, and today our CEO, Edward Haeggstrom; CFO, Albert Haeggstrom; CCO, Christian Jones; and CEO, Peter Hanninen will present to you. This presentation is webcasted through Investor Caer and there's also the possibility to call in and listen by phone.
The presentation slides, shown here, throughout the webcast can also be found, at the web page in the investor section. At the end, we will hold a Q&A and it's possible to ask questions if you call in.
Today, we will start with strategy and key business highlights, then financials, then commercial, and we conclude with product kernels and biologics. With these words, our CEO and founder, Edward Haeggstrom, please go ahead.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
